Japanese Pharmaceutical Industry Realignment Speeds Up In 2008: Interview With President Of Dainippon Sumitomo
This article was originally published in PharmAsia News
Executive Summary
In an interview with Yomiuri News, Dainippon Sumitomo President Kenjiro Miyatake noted 2008 drug prices are estimated to be over five percent lower
You may also be interested in...
Danippon Sumitomo Deal With BioSeek Could Be Model For Other Japanese Pharmas – BIO-Asia
TOKYO - BioSeek's deal last week with Danippon Sumitomo Pharma could be a model for additional deals between the Burlington, Calif.-based platform company and Japanese pharmas looking to de-risk preclinical decisions, according to BioSeek VP-Technology & Alliances Ivan Plavec
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.